ed at 4 mg/day. It is taken in tablet form once or twice a day before or after meals.

The controversy over this drug started with the release of the New England journal of Medicine report on 21 May 2007 that suggested that there was a 43% increased risk of heart attack for users of Rosiglitazone by comparison to other diabetic drugs or placebo cases.

The FDA has issued an alert over Rosiglitazone. It has stated that it will continue to study the

Avandia is a oral anti-diabetic drug that is used to treat type 2 diabetes. The drug has recently been the subject of a report that suggests that it may increase the chance of heart failure. This article will look at how Avandia treats type 2 diabetes. The article also deals with what to do if you are currently taking the drug in the light of this new information.

It is estimated that some 18 million Americans and 200 million worldwide are afflicted by type 2 diabetes. It is the most common form of the disease and is one of the fastest growing diseases according to the World Health Organization (WHO) that estimates the number of people afflicted by the disease in 2030 to be around 366 million. Type 2 diabetes is an advanced form of insulin resistance. Insulin is required by the body to convert glucose to energy. A by-product of this is that the level of glucose is lowered in the blood. People with type 2 diabetes produce insulin but it is either ineffective or is at an insufficient quantity. The body is said to be resistant to insulin and some form of drug is needed to help regulate the blood glucose level.

In America, Avandia has been used to regulate the blood glucose level after it was approved by the Food and Drug Administration (FDA) in 1999. It has proved a popular drug since that time and millions of prescriptions have been written for it.

Avandia is the trade name of the pharmaceuticals company GlaxoSmithKline for the generic drug Rosiglitazone. Rosiglitazone is often termed an insulin sensitizer because it attaches to insulin receptors on cells (the peroxisome proliferator-activated receptors (PPARs)) that make them more responsive to insulin. This has the effect of utilizing the glucose to provide energy while reducing the glucose level in blood.

Rosiglitazone therapy is usually started at 4 mg/day. It is taken in tablet form once or twice a day before or after meals.

The controversy over this drug started with the release of the New England journal of Medicine report on 21 May 2007 that suggested that there was a 43% increased risk of heart attack for users of Rosiglitazone by comparison to other diabetic drugs or placebo cases.

The FDA has issued an alert over Rosiglitazone. It has stated that it will continue to study the f

type 2 diabetes. It is the most common form of the disease and is one of the fastest growing diseases according to the World Health Organization (WHO) that estimates the number of people afflicted by the disease in 2030 to be around 366 million. Type 2 diabetes is an advanced form of insulin resistance. Insulin is required by the body to convert glucose to energy. A by-product of this is that the level of glucose is lowered in the blood. People with type 2 diabetes produce insulin but it is either ineffective or is at an insufficient quantity. The body is said to be resistant to insulin and some form of drug is needed to help regulate the blood glucose level.

In America, Avandia has been used to regulate the blood glucose level after it was approved by the Food and Drug Administration (FDA) in 1999. It has proved a popular drug since that time and millions of prescriptions have been written for it.

Avandia is the trade name of the pharmaceuticals company GlaxoSmithKline for the generic drug Rosiglitazone. Rosiglitazone is often termed an insulin sensitizer because it attaches to insulin receptors on cells (the peroxisome proliferator-activated receptors (PPARs)) that make them more responsive to insulin. This has the effect of utilizing the glucose to provide energy while reducing the glucose level in blood.

Rosiglitazone therapy is usually started at 4 mg/day. It is taken in tablet form once or twice a day before or after meals.

The controversy over this drug started with the release of the New England journal of Medicine report on 21 May 2007 that suggested that there was a 43% increased risk of heart attack for users of Rosiglitazone by comparison to other diabetic drugs or placebo cases.

The FDA has issued an alert over Rosiglitazone. It has stated that it will continue to study the

diabetes produce insulin but it is either ineffective or is at an insufficient quantity. The body is said to be resistant to insulin and some form of drug is needed to help regulate the blood glucose level.

In America, Avandia has been used to regulate the blood glucose level after it was approved by the Food and Drug Administration (FDA) in 1999. It has proved a popular drug since that time and millions of prescriptions have been written for it.

Avandia is the trade name of the pharmaceuticals company GlaxoSmithKline for the generic drug Rosiglitazone. Rosiglitazone is often termed an insulin sensitizer because it attaches to insulin receptors on cells (the peroxisome proliferator-activated receptors (PPARs)) that make them more responsive to insulin. This has the effect of utilizing the glucose to provide energy while reducing the glucose level in blood.

Rosiglitazone therapy is usually started at 4 mg/day. It is taken in tablet form once or twice a day before or after meals.

The controversy over this drug started with the release of the New England journal of Medicine report on 21 May 2007 that suggested that there was a 43% increased risk of heart attack for users of Rosiglitazone by comparison to other diabetic drugs or placebo cases.

The FDA has issued an alert over Rosiglitazone. It has stated that it will continue to study the

Avandia is the trade name of the pharmaceuticals company GlaxoSmithKline for the generic drug Rosiglitazone. Rosiglitazone is often termed an insulin sensitizer because it attaches to insulin receptors on cells (the peroxisome proliferator-activated receptors (PPARs)) that make them more responsive to insulin. This has the effect of utilizing the glucose to provide energy while reducing the glucose level in blood.

Rosiglitazone therapy is usually started at 4 mg/day. It is taken in tablet form once or twice a day before or after meals.

The controversy over this drug started with the release of the New England journal of Medicine report on 21 May 2007 that suggested that there was a 43% increased risk of heart attack for users of Rosiglitazone by comparison to other diabetic drugs or placebo cases.

The FDA has issued an alert over Rosiglitazone. It has stated that it will continue to study the

ed at 4 mg/day. It is taken in tablet form once or twice a day before or after meals.

The controversy over this drug started with the release of the New England journal of Medicine report on 21 May 2007 that suggested that there was a 43% increased risk of heart attack for users of Rosiglitazone by comparison to other diabetic drugs or placebo cases.

The FDA has issued an alert over Rosiglitazone. It has stated that it will continue to study the findings over the drug but that people taking the drug should consult their doctor. People that have suffered any form of heart problems and take this drug should definitely see their doctor. The American Diabetic Association has also advocated a don't panic attitude; consult your doctor but don't stop taking your prescription unless advised by a qualified medical practitioner.